A Delaware federal jury said on Friday that Revance Therapeutics owes AbbVie's Allergan Inc $56 million after finding that ...

AbbVie's dividends add to its attractiveness at an uncertain time, adding to robust price returns over time. Click here to ...

AbbVie (ABBV) reached $187.12 at the closing of the latest trading day, reflecting a +1.23% change compared to its last close.

ABBV's neuroscience sales are projected to jump 15% in Q2, driven by Botox Therapeutic, Vraylar and oral migraine drug gains.

AbbVie and its subsidiary Allergan have had a long run of unchallenged success in the market with cosmetic and therapeutic ...

Shares of AbbVie Inc. ABBV advanced 1.22% to $187.11 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.06% to 6,309.62 and the ...

AbbVie Inc. (NYSE: ABBV) is one of the high-margin pharma stocks to buy now . AbbVie Inc. (NYSE:ABBV) received a slight boost ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corp. (NVDA), Amazon.com, Inc.

A federal jury July 18 said Revance Therapeutics' skin medication infringed on patents for anti-wrinkle treatment Botox and owes AbbVie-owned Allergan $56 million.

The U.K.-based drug maker plans to invest $50 billion in the United States as the industry seeks to appease President Trump.

This was the stock's second consecutive day of losses.

A federal jury in Delaware found that Revance's rival product infringed patents for Allergan's market-leading neurotoxin ...